title: Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction.
abstract: OBJECTIVE
  We investigated the effects of short-term tezosentan treatment on cardiac function, pulmonary edema and long-term evolution of heart failure (HF) in a rat model of myocardial infarction (MI).
  
  
  BACKGROUND
  Endothelin (ET) may play a major role in the progression from MI to HF. Tezosentan is a new dual ET(A)/ET(B) receptor antagonist.
  
  
  METHODS
  Rats were subjected to coronary artery ligation and were treated with either vehicle or tezosentan (10 mg/kg IV bolus) at 1 h and 24 h after MI. Cardiac hemodynamics and lung weight were measured at 48 h after MI. Survival was assessed over a five-month period.
  
  
  RESULTS
  At 48 h after ligation, vehicle-treated rats developed HF, as evidenced by a marked increase in left ventricular end-diastolic pressure (LVEDP), reduction in dP/dt(max) and mean arterial pressure (MAP), and development of pulmonary edema. Tezosentan treatment attenuated the increase in LVEDP and in lung weight and slightly reduced MAP without affecting dP/dt(max). Infarct size was not modified by tezosentan. Despite the fact that treatment with tezosentan was stopped after 24 h, the initial tezosentan administration significantly reduced cardiac hypertrophy (22%) and decreased mortality by 51% at five months (50% survival vs. 19% survival in vehicle-treated rats, p < 0.001).
  
  
  CONCLUSIONS
  Tezosentan administered during the first day after MI in rats, in addition to improving acutely hemodynamic conditions, markedly increases long-term survival. This increase is associated with a decrease of pulmonary edema and prevention of cardiac hypertrophy. Tezosentan could be a safe and useful therapeutic agent in the prevention and treatment of ischemic HF.
authors.affiliation: Actelion Pharmaceuticals Ltd., Allschwil, Switzerland. martine.clozel@actelion.com
authors.forename: Martine
authors.initials: M
authors.lastname: Clozel
authors.forename: Changbin
authors.initials: C
authors.lastname: Qiu
authors.forename: Chang-Shen
authors.initials: CS
authors.lastname: Qiu
authors.forename: Patrick
authors.initials: P
authors.lastname: Hess
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Clozel
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D065128:Endothelin Receptor Antagonists; D006439:Hemodynamics / Q000187:drug effects; D008168:Lung / Q000033:anatomy & histology; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy*; D009929:Organ Size; D011654:Pulmonary Edema / Q000517:prevention & control; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D065128:Endothelin Receptor Antagonists; D011725:Pyridines; D013777:Tetrazoles; D014665:Vasodilator Agents; C120582:tezosentan